PEGylated Proteins Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The PEGylated Proteins Market is Segmented by Product Type (PEGylation Kits and Reagents (Monofunctional Linear PEGs, Bifunctional PEGs), Services, and Other Product Types), Protein Type (Colony-stimulating Factor, Interferon, Erythropoietin, and Other Protein Types), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

PEGylated Proteins Market Overview
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 9.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The PEGylated proteins market is expected to register a CAGR of 9.3% over the forecast period.

The impact of COVID-19 on the PEGylated proteins market is expected to be minimal. According to the study published in Biomaterial in June 2021, titled "PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses" PEGylated nanoparticle albumin-bound (PNAB) -steroidal ginsenoside can effectively lower histone H4 and NETosis-related factors in the plasma and ameliorate SREBP2-mediated systemic inflammation in SARS-CoV-2 ICU patients. PNAB-steroidal ginsenoside medications may be useful in treating symptoms associated with severe SARS-CoV-2 patients, such as coagulation and cytokine storm. Thus, given the extensive research activities carried out based on PEGylation technology, the COVID-19 pandemic is expected to impact the market; however, the accurate impact is still unclear.

The major factor attributing to the growth of the market is the increasing prevalence of chronic diseases like cancer, kidney diseases, and rheumatoid arthritis. According to GLOBOCAN 2020, the new cancer cases that were diagnosed accounted for 19,292,789 in 2020 globally, with 9,958,133 deaths due to cancer. Moreover, as per the same source, among all cancers, breast cancer accounted for 2,261,419 new cancer cases, followed by lung cancer with 2,206,771 new cases, prostate cancer with 1,414,259, and colon cancer with 1,148,515 new cases in 2020. Additionally, as per the Global HIV and AIDS Statistics 2021 fact sheet by the Joint United Nations Program on HIV/AIDS (UNAIDS), 37.7 million people globally were living with HIV in 2020. Thus, with the growing burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others globally, the demand for developing medicine is also expected to increase, which will boost the research on protein thus driving the PEGylated protein market.

Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting the market growth. For instance, in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.58 million) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourneyBiologics S.A. In addition, there is rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving the efficacy. However, drug failure and drug recalls are the major drawbacks of the market.

Scope of the Report

As per the scope of the report, PEGylation is the process of binding or alteration of biological molecules by conjugation with polyethylene glycol is known as PEGylation. PEGylation enhances the stability and solubility of the drug and declines immunogenicity by changing the electrostatic binding, confirmation, and hydrophobicity of the molecule. The PEGylated Proteins Market is Segmented by Product Type (PEGylation Kits and Reagents (Monofunctional Linear PEGs, Bifunctional PEGs), Services, and Other Product Types), Protein Type (Colony-stimulating Factor, Interferon, Erythropoietin, and Other Protein Types), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product Type
PEGylation Kits and Reagents
Monofunctional Linear PEGs
Bifunctional PEGs
Other Product Types
By Protein Type
Colony-stimulating Factors
Other Protein Types
By End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic Research Institutes
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Colony-stimulating Factors Segment is Expected to Grow at the Highest Rate in the Forecast Period

Colony-stimulating factors are substances that accelerate the production of blood cells and elevate their ability to function. They do not directly influence tumors but have a role in stimulating blood cells, and hence, these factors can be beneficial in supporting a person's immune system during cancer treatment.

According to the research article published in Frontier in Oncology in April 2022, titled "Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial" a half-dose of prophylactic granulocyte-colony stimulating factor (G-CSF) can effectively and safely prevent neutropenia in patients with various malignancies who have an intermediate risk of febrile neutropenia (FN) combined with 1 patient-specific risk during chemotherapy. Thus, the above benefits of the colony-stimulating factors in the treatment of tumors are expected to boost segment growth.

Furthermore, the market growth of the segment is due to the increasing incidence of cancer across the globe, and the usage of peptide treatment for cancer. According to Globocan 2020, the incidence of cancer cases in 2020 was estimated to be 19,292,789 cases worldwide, with nearly 9,958,133 deaths due to cancer in 2020. Additionally, the five-year prevalent cases were estimated as 50,550287 cancer cases by 2020, with a 201.0 age-standardized incidence rate globally. Thus, the high incidence of cancer surges the need for colony-stimulating factors in its effective treatment and thus drives segment growth.

Furthermore, the expanded awareness among patients and healthcare professionals regarding the adverse effects of other methods of cancer treatments, such as chemotherapy and radiation therapy, is a major factor for the growing focus on alternative therapeutics such as pegylated peptide-based drugs. Hence, the aforementioned factors are expected to positively drive the growth of the colony-stimulating factors segment over the forecast period.

Antithrombin Market

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America is expected to dominate the overall PEGylated protein market throughout the forecast period. The presence of key players, the high prevalence of chronic diseases in the region, established healthcare infrastructure, and growing awareness of advanced treatment options among the American population are some of the key factors accountable for its large share in the market. In April 2021, the Canadian Cancer Society data stated that nearly one in every two Canadians would develop cancer at some point in their lives. While it is more common in men (45%), it can be fatal to one in every four Canadians. Thus, the growing prevalence of chronic diseases is expected to rise in research and development activity driving the growth of the market in the region over the forecast period.

Furthermore, the rising geriatric population and the high incidence of chronic diseases are also expected to play a vital role in the growth of the studied market. According to the estimates of the American Cancer Society, in 2022, it is expected that 79,000 new instances of kidney cancer are likely to be diagnosed in the United States, including 50,290 cases in males and 28,710 cases in women. The top 10 malignancies for both men and women include kidney cancer. Men have about a 1 in 46-lifetime risk of having kidney cancer (2.02%). For women, the lifetime risk is approximately 1 in 80. (1.03%). Thus, the growing prevalence of chronic diseases in the region is likely to propel the growth of the market.

Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the factors expected to drive market growth. For instance, in February 2021, Nautilus merged with Arya III, a special purpose acquisition company (SPAC), with an initial investment of USD 350 million to ramp up work developing its protein analysis technology for drug discovery and diagnostic applications.


Competitive Landscape

The PEGylated proteins market is moderately consolidated and consists of few major players. Some of the companies currently dominating the market are Merck KGaA, Thermo Fisher Scientific Inc., NOF America Corporation, JenKem Technology USA Inc., Creative PEGworks, and Celares GmbH, among others. The companies have been following various strategies such as acquisitions, partnerships, investments in research activities, and new product launches to sustain among the competitors in the global market.

Recent Developments

  • In July 2022, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a favourable opinion, recommending the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.
  • In February 2022, Merck KGaA announced the acquisition of Exelead, a biopharmaceutical CDMO specializing in PEGylated products and complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Prevalence of Chronic Diseases

      2. 4.2.2 Increasing Adoption of Protein Treatments

      3. 4.2.3 Rise in Research and Development Funding by Key Players

    3. 4.3 Market Restraints

      1. 4.3.1 Drug Failures and Drug Recalls

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Product Type

      1. 5.1.1 PEGylation Kits and Reagents

        1. Monofunctional Linear PEGs

        2. Bifunctional PEGs

      2. 5.1.2 Services

      3. 5.1.3 Other Product Types

    2. 5.2 By Protein Type

      1. 5.2.1 Colony-stimulating Factors

      2. 5.2.2 Interferons

      3. 5.2.3 Erythropoietin

      4. 5.2.4 Other Protein Types

    3. 5.3 By End User

      1. 5.3.1 Pharmaceutical and Biotechnology Companies

      2. 5.3.2 Contract Research Organizations

      3. 5.3.3 Academic Research Institutes

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Merck KGaA

      2. 6.1.2 Thermo Fisher Scientific Inc.

      3. 6.1.3 NOF America Corporation

      4. 6.1.4 JenKem Technology USA Inc.

      5. 6.1.5 Creative PEGworks

      6. 6.1.6 Celares GmbH

      7. 6.1.7 Quanta BioDesign Ltd

      8. 6.1.8 Biogen Inc.

      9. 6.1.9 F. Hoffmann-La Roche Ltd

      10. 6.1.10 Horizon Pharma PLC

      11. 6.1.11 Pfizer Inc.

      12. 6.1.12 Takeda Pharmaceuticals U.S.A., Inc.(Shire PLC)

      13. 6.1.13 Quiapeg Pharmaceuticals Holding AB

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global PEGylated Proteins Market market is studied from 2019 - 2027.

The Global PEGylated Proteins Market is growing at a CAGR of 9.3% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Merck KGaA, Thermo Fisher Scientific, Inc, NOF America Corporation, JenKem Technology USA, Inc, Creative PEGworks are the major companies operating in Global PEGylated Proteins Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!